Nyagan AG, Maitre M. A single acute pharmacological dose of ␥-hydroxybutyrate modifies multiple gene expression patterns in rat hippocampus and frontal cortex. Physiol Genomics 41: 146-160, 2010. First published January 26, 2010 doi:10.1152/physiolgenomics.00208.2009.-␥-Hydroxybutyrate (GHB) is a natural brain neuromodulator that has its own enzymatic machinery for synthesis and degradation, release, and transport systems and several receptors that belong to the G protein-coupled receptor (GPCR) family. Targeting of this system with exogenous GHB is used in therapy to induce sleep and anesthesia and to reduce alcohol withdrawal syndrome. GHB is also popular as a recreational drug for its anxiolytic and mild euphoric effects. However, in both cases, GHB must be administered at high doses in order to maintain GHB concentrations in brain of ϳ800 -1,000 M. These high concentrations are thought to be necessary for interactions with lowaffinity sites on GABA B receptor, but the molecular targets and cellular mechanisms modulated by GHB remain poorly characterized. Therefore, to provide new insights into the elucidation of GHB mechanisms of action and open new tracks for future investigations, we explored changes of GHB-induced transcriptomes in rat hippocampus and prefrontal cortex by using DNA microarray studies. We demonstrate that a single acute anesthetic dose of 1 g/kg GHB alters a large number of genes, 121 in hippocampus and 53 in prefrontal cortex; 16 genes were modified simultaneously in both brain regions. In terms of molecular functions, the majority of modified genes coded for proteins or nucleotide binding sites. In terms of Gene Ontology (GO) functional categories, the largest groups were involved in metabolic processing for hippocampal genes and in biological regulation for prefrontal cortex genes. The majority of genes modified in both structures were implicated in cell communication processes. Western blot and immunohistochemical studies carried out on eight selected proteins confirmed the microarray findings.
THE IDEA that ␥-hydroxybutyrate (GHB) possesses important functions as a neuromodulator in brain is now supported by numerous results (49) . This endogenous compound is synthesized from GABA and is coreleased with it during GABA synaptic activity (51) . Endogenous GHB concentrations in brain tissue range from 0.5-1 M to 10-25 M (22) but the fluctuations of GHB in the extracellular spaces, namely in the synapses, have never been measured. Successively, specific GHB binding was described in the brain of several animal species and in humans (6, 13, 31) , and more recently GHB receptors have been cloned from both human and rat brain (2, 3) . These GHB receptors appear to be heterogeneous with respect to their architecture and pharmacology, despite the fact they belong to G protein-coupled receptor (GPCR) classes. In particular, the GHB analog NCS-382 possesses antagonistic, partial agonist, or no activity, depending on the receptor. Additionally, several GHB receptors desensitize rapidly upon GHB stimulation (11, 41, 56) .
Pharmacological or therapeutically active doses of GHB are high: 0.5-1 g/kg in rats, 9 g during the night to treat narcolepsy in humans, and several grams in self-administration for recreational purposes. These high doses are necessary in order to induce GHB concentrations in brain of ϳ800 -1,000 M (43, 59) . It is generally considered that the main/unique target that mediates therapeutic effects of GHB is GABA B receptor(s) (39) . However, GABA B -specific agonists like baclofen possess several different pharmacological effects and therapeutic indications. GHB is a weak agonist for these receptors (47) , so the brain GHB concentration must be high to induce significant effects like anxiolysis and sedation. However, sleep or anesthesia and in some cases drug dependence (74) are generally attributed to the stimulation of GABA A receptors. We propose that GHB at high doses targets several brain systems including GABA B receptors but also modulates the whole endogenous GHB system, inducing a potentiation of the entire GABA system through GABA A receptor stimulation.
Beside these metabolic and functional proteomic adaptations, direct or indirect genomic regulation most probably takes place. These modifications in gene expression may have a fundamental role in the mechanism of action of GHB. Almost nothing is known about transcriptional changes that could explain the specificity of GHB effects after a single acute dose of this compound and the installation of behavioral changes. We used oligonucleotide microarrays to identify genes that are differentially expressed in hippocampus and frontal cortex of rats treated 2 h before RNA extraction by a therapeutic/anesthetic dose of GHB and compared these with rats receiving saline.
The main objective of our study was to identify genes modified after GHB used at a therapeutic dose. We hypothesized that the mechanisms of GHB effects in brain are far more complex than generally thought and possess a specific signature at the level of gene expression. In addition, the specific modification of brain transcriptome under the drug's influence could generate new hypotheses about its molecular mechanisms of action, together with new approaches to select new drugs with a more active profile. We focus on the gene population most modified by the treatment in two important brain regions that express GHB receptors. Among these populations, we described 16 genes simultaneously regulated in both hippocampus and frontal cortex of treated rats. Modified genes were classified by their Gene Ontology (GO) terms, and we extracted the significant Molecular Function and Biological Process terms of these genes. To confirm the gene modifications of expression, we arbitrarily selected eight modified genes possessing important brain functions and studied their protein products quantitatively by Western blot and immunohistochemistry.
MATERIALS AND METHODS

Animals and Drug Treatments
Adult male Wistar rats (250-to 300-g body wt) were used for all experiments. They were housed three per cage and kept at constant temperature (21 Ϯ 1°C) with a regular light-dark schedule (7 AM-7 PM). Food and water were available ad libitum. Procedures involving animals and their care were conducted in compliance with a European Communities Council Directive (86/609/EEC) and under the supervision of authorized investigators. In addition, all of the protocols were reviewed and approved by the Alsace Head Office of the French Department of Veterinary and Public Health Guide for the Care and Use of Laboratory Animals with the agreement number 67-186. Animals were injected intraperitoneally with saline (1 ml/kg) or GHB (1 g/kg) 2 h before being killed and decapitated. Hippocampus and prefrontal cortex were rapidly excised under sterile conditions and immediately used or stored at Ϫ80°C until RNA extraction.
RNA Isolation and Microarray Analysis
Total RNA was extracted from frozen hippocampus and prefrontal cortex with the Nucleospin RNAL protocol (Macherey-Nagel, Düren, Germany). This protocol included a treatment of isolated RNA by DNase I. The different batches of RNA were further purified with RNeasy columns (Qiagen, Courtaboeuf, France). Three biological replicates from three different rats were prepared for each cerebral structure. Integrity and purity of RNA were checked by spectrophotometry and capillary electrophoresis with the Bioanalyzer 2100 RNA and 6000 Nano Kit from Agilent Technologies (Palo Alto, CA). cDNA were synthesized with the Superscript Choice system (Invitrogen), and then biotin-labeled cRNAs were obtained with the Affymetrix IVT labeling kit (Affymetrix, Santa Clara, CA). After purification, 10 g of fragmented cRNA was hybridized to the Affymetrix GeneChip Rat Genome 230 2.0 Array (31,042 probe sets including Ͼ28,000 rat genes), and the chips were automatically washed and stained with streptavidin-phycoerythrin and an Affymetrix fluidics station 450. Finally, arrays were scanned at 570 nm with a resolution of 1.56 m/pixel with the Gene Chip Scanner 3000 7G from Affymetrix. Raw images (CEL format files) were generated with Affymetrix GeneChip Operating Software (GCOS 1.4).
Microarray Data Analysis
Gene expression values. The calculation for selecting differentially expressed genes was based on data processed with the dChip algorithm (46) . Data were first normalized with the rank invariant method at probe level, then the Model Based Index algorithm was used with the PM/MM for calculating gene expression indexes. The dChip algorithm also allows association of detection level (P for present, A for absent, and M for marginal) to probe set. The replicate samples from the test and the reference were averaged, and a fold change (FC) was calculated for each probe set. Permutation was used to control the false discovery rate of the final list (8) .
Replicate reproducibility. To assess reproducibility, we computed the correlation between the expression values of the three biological replicates of each cerebral structure. All values were above r ϭ 0.97, which indicates good reproducibility.
Gene selection. Stringent filtering criteria were used to identify genes whose expression level was significantly changed between two stages. We performed a Student's t-test analysis to compare treated versus untreated rats for each structure. We selected genes that met all of the following requirements: 1) Student's t-test P value Ͻ0.05 for the three replicates of each treated versus nontreated rat; 2) FC calculated with the mean of the three replicates is either Ն1.5 or Յ0.67 (Ϫ1.5-fold change) for both comparisons; 3) at least a minimum of two values must be identified as "present" (P), and one of the values of the microarray signal must be superior to 4 for each sample group.
Analysis of results. The Database for Annotation, Visualization, and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.gov/) was used to extract relevant GO terms (http://godatabase.org/) for our groups of genes with respect to a set of reference genes (typically the remaining genes) (33) . The terms are considered to be relevant by the application of a modified Fisher's exact test (EASE score). The P value Յ0.05 was adopted to measure significant gene enrichment in annotation terms of our population of genes compared with random chance for rat background genes.
In another analysis, Online Mendelian Inheritance in Man (OMIM; www.ncbi.nlm.nih.gov/omim/) and UniProt (www.ebi.ac.uk/uniprot/) were used to provide information on gene and protein functions. OMIM and the Gene Expression Omnibus Database are provided in the public domain by the National Center for Biotechnology Information (Bethesda, MD).
Antibodies
The following antibodies were used: GABA A receptor ␥2 antibody (anti-Gabrg2, rabbit polyclonal IgG, 1/500), dopamine receptor D3 antibody (anti-Drd3, rabbit polyclonal IgG, 1/500), dual-specificity phosphatase 1 antibody (anti-Dusp1, goat polyclonal, 1/500), brainspecific angiogenesis inhibitor 1-associated protein 2 antibody (antiBaiap2, rabbit polyclonal IgG, 1/500), and muscarinic acetylcholine receptor M4 antibody (anti-Chrm4, rabbit polyclonal IgG, 1/1 000) (all purchased from Abcam, Cambridge, UK). Prolactin receptor antibody (anti-Prlr, goat polyclonal, 1/500), cFos antibody (anti-cFos, rabbit polyclonal, 1/500) and serum/glucocorticoid-regulated kinase 1 antibody (anti-Sgk, mousse monoclonal, 1/500) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Immunoprecipitation
One to two micrograms of the various monoclonal antibodies or two to four micrograms of the different polyclonal antibodies were added to cell lysates and mixed. Fifty microliters (monoclonal antibodies) or one hundred microliters (polyclonal antibodies) of Protein G MicroBeads (Miltenyi Biotec) were added, mixed, and incubated for 30 min at 0°C. Columns (Miltenyi Biotec) were placed in the magnetic field of the MACS Separator (Miltenyi Biotec). The Columns were rinsed with 200 l of lysis buffer, and then cell lysates were applied to the different columns and allowed to run through. The columns were rinsed with 4 ϫ 200 l of a suitable buffer [150 mM NaCl, 1% IGEPAL CA630 (NP-40), 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris·HCl pH 8.0]. Thereafter, columns were rinsed with 100 l of low-salt wash buffer (20 mM Tris·HCl pH 7.5). Twenty microliters of preheated (95°C) SDS gel loading buffer was applied onto the column matrix and incubated for 5 min at room temperature. Columns were eluted with 50 l of preheated (95°C) SDS gel loading buffer. Eluted immunoprecipitates were then analyzed by SDS-PAGE electrophoresis.
Western Immunoblotting
Equal amounts of protein samples were separated along with molecular weight markers (Fermentas, Hanover, MD) in 10% polyacrylamide gels. After electrophoresis, the various polyacrylamide gels were transferred onto 0.2-m nitrocellulose membranes (BioRad, Hercules, CA) and detected with the specific antibodies listed above, as described previously. The amount of proteins loaded was controlled by measuring the coloration by Coomassie Blue R-250. Species-specific immunoglobulin G horseradish peroxidase (IgG-HRP) secondary antibodies (P.A.R.I.S., Compiègne, France) were used. Blots were developed with chemiluminescent substrate (Pierce Biotechnology, Rockford, IL), and autoradiographs were performed with BioMax MR film (Kodak, Rochester, NY).
Protein labeling was quantified by measuring the integrated optical density (OD) of the bands, after subtracting background by Image J software. Image analysis of the blots was performed on OD-calibrated images captured with Adobe Photoshop software (Adobe Systems).
Immunohistochemistry
Animals were injected intraperitoneally with NaCl (0.9%) or GHB (1 g/kg). Two hours after injection, rats were deeply anesthetized by intraperitoneal injection of 1 ml (5.6% wt/vol) pentobarbital sodium solution (CEVA Santé Animal, Libourne, France) and perfused transcardially with a fixative solution containing 4% freshly depolymerized paraformaldehyde (Sigma-Aldrich, Saint-Quentin, France) in 0.1 M phosphate buffer (pH 7.4). This solution was chilled before being injected into anesthetized animals with a peristaltic pump at a flow rate of 25 ml/min until 1 ml/g body wt was reached. The brains were quickly removed and left for 2 h at room temperature in the same fixative solution. After fixation, brains were rinsed six times for 5 min in Tris-buffered saline (TBS, pH 7.4) to block residual aldehyde groups. Brain sections were dissected according to the Paxinos and Watson coordinates (54) . Coronal sections (50 -80 m) were cut with a vibratome (Leica VT 1000 M) and collected in TBS.
Floating sections were immunostained as follows. Tissue slides were rinsed with TBS and then blocked for 20 min with 10% normal bovine serum (NBS) in TBS. Sections were incubated overnight at 4°C with one of the antibodies listed above, at optimal dilution. Sections were then washed in TBS and incubated with speciesspecific IgG-HRP secondary antibodies for 3 h. These antibodies were goat anti-rabbit IgG (HϩL), (BI2407, final dilution 1/200), goat anti-mousse IgG (HϩL), (BI2413C, final dilution 1/200), or rabbit anti-goat IgG (HϩL), (BI2403, final dilution 1/200) (P.A.R.I.S.). Sections were washed again (6 times during 5 min) with TBS. Peroxidase activities were detected with a freshly prepared solution of 4-chloro 1-naphthol (0.2 mg/ml) in TBS containing 0.006% (wt/vol) hydrogen peroxide. After being washed with TBS, the sections were mounted in glycerol-TBS (vol/vol) before microscopic analysis with a microscope (Leica DMRB) equipped with a digital camera (Axiocam, Zeiss, Germany).
Immunolabeled sections were visualized by using a ϫ25 objective lens. All analyses were carried out in comparable areas under the same optical and light conditions. Black-and-white images were digitized and viewed on a computer with LAS software (Leica).
The immunolabeled patterns were isolated by using thresholding, and the thresholded area was measured. In parallel, the mean and maxima of OD were measured for each image. The OD measurement for each image is the mean gray of the pixels inside the selected area of the image, with a 256 gray scale as reference. OD increases with the intensity of labeling between a minimum (0: white) and a maximum (255: black). For each condition of staining, the quantification was normalized at 100% for control rats in order to compare treated with control rats as in microarrays and Western blot studies.
RESULTS
GHB Alters Gene Expression Patterns in Hippocampus and Prefrontal Cortex
In an attempt to identify all the genes whose expression changes were associated with the administration of a therapeutic dose of GHB, microarray transcription profiles were obtained from hippocampus and prefrontal cortex of rats treated with 1 g/kg GHB and compared with those in control rats administered saline. The proportion of probe sets designated as "present" in the hippocampus by the Affymetrix software was 54 Ϯ 0.88% and 57.9 Ϯ 3.09% for GHB-treated rats and control rats, respectively, with no significant fluctuations (P ϭ 0.27). In the prefrontal cortex, the proportion of probe sets designated as "present" by the Affymetrix software was 63.33 Ϯ 0.96% and 65.03 Ϯ 1.41% for GHB-treated rats and control rats, respectively (nonsignificant fluctuations, P ϭ 0.39). These results confirmed that multiple probe sets were regulated by GHB treatment. However, the percentage of probe sets designated as "present" by the Affymetrix software was significantly different between hippocampus and prefrontal cortex. It might be that GHB targets and modifies specific circuits in these two brain regions and does not possess a uniform molecular and functional role in whole brain. This is conceivable for a neuromodulator that possesses an uneven distribution of targets in brain, together with a heterogeneous regional modulation of its functions. Accordingly, the majority of probe sets regulated by GHB treatment seem to be different and/or differentially expressed in each cerebral structure.
Six hundred twenty-one probe sets representing three hundred sixty-four genes (Ͻ2% of the arrayed cDNA) showed 1.5-fold or greater changes in expression in the hippocampus and/or in the prefrontal cortex of the rat brain after systemic administration of a therapeutic dose of GHB. The most prominently regulated class of probe sets was expressed sequence target (EST), which accounted for 40.0% of all probe sets regulated in the hippocampus and 43.0% of all probe sets regulated in the prefrontal cortex. Among these 621 probe sets, 24.2% were affected only in the prefrontal cortex (151 probe sets), 72.4% were affected only in the hippocampus (449 probe sets), and 3.4% (21 probe sets) were affected in both brain structures. Approximately the same number of probe sets were up-or downregulated in the two structures (304 and 317, respectively); however, 58.2% of probe sets were upregulated in the hippocampus and 36.3% in the prefrontal cortex, while 7.5% of probe sets (only 1) were downregulated in both regions.
Genes Having Greatest Modifications in Their Expression Patterns in Both Brain Regions After Therapeutic Acute Dose of GHB
The 470 probe sets modified in the hippocampus by GHB treatment represented 282 genes that were differentially expressed; 89 genes showed a 1.5-to 2-fold increase of expression changes, 21 genes showed an increase between 2-and 3-fold, and 11 genes presented an increase of expression change Ͼ3-fold (Table 1 ). In contrast, 124 genes showed a 1.5-to 2-fold decrease, 27 genes presented a 2-to 3-fold decrease, and 10 genes had a reduction of Ͼ3-fold in their expression patterns (Table 1) .
In the prefrontal cortex, the 172 probe sets altered by the treatment represented 98 genes differentially expressed. In this last region, 53 genes showed a 1.5-to 2-fold increases while 14 genes showed an increase between 2-and 3-fold in their transcription (Table 2 ). By contrast, 25 genes exhibited a 1.5-to 2-fold decrease and 7 genes showed a reduction Ͼ2-fold in their expression (Table 2) .
Genes with Simultaneous Altered Expression in Both Brain Regions After Acute Therapeutic Dose of GHB
Twenty-one probe sets showed 1.5-fold or greater changes in their expression in both the hippocampus and prefrontal cortex. These probe sets represented 16 genes (Table 3 ). Only one gene showed an increase in expression greater than fourfold, and this gene was represented by two different probe sets; the associated gene and/or protein was glycerol-3-phosphate dehydrogenase 1 (Gdp1). Expression of only gene (tumor necrosis factor receptor superfamily, member 11b; osteoprotegerin or OPG) was reduced after GHB treatment in the two structures. 
Molecular Functions of Genes with Altered Expression After Therapeutic Acute Dose of GHB
The probe sets modified by high doses of GHB were in a broad range of Molecular Function categories when classified according to GO terms by DAVID, the web-accessible programs. The numbers of genes significantly affected and exhibiting some referenced Molecular Function terms were 252 (53.6%) in the hippocampus and 98 (57.0%) in the prefrontal cortex (Supplemental Table S1 ). 1 In the hippocampus, the Molecular Function GO terms modified by GHB treatment could be classified in three principal categories: 1) "binding" (GO: 0005488, P ϭ 4.23 ϫ 10 Ϫ5 , 40.73% of genes concerned), 2) "catalytic activity" (GO: 0003824, P ϭ 0.0029, 22.40% of genes concerned), and 3) "transcription regulator activity" (GO: 0030528, P ϭ 0.037, 6.31% of genes concerned) (Fig. 1) .
The "binding" GO term was the most important in terms of number of genes and could be divided into 13 subgroups including "protein binding" (GO: 0005515, P ϭ 5.05 ϫ 10 Ϫ4 , 23.83% of genes concerned) or "nucleotide binding" (GO: 0000166, P ϭ 0.00371, 9.98% of genes concerned). In the "catalytic activity" GO term, 11 subgroups could be identified, such as "protein kinase activity" (GO: 0004672, P ϭ 1.11 ϫ 10 Ϫ5 , 5.91% of genes concerned), which was the most significant of the group. The "transcription regulator activity" GO term was only represented by one subgroup, "RNA polymerase II transcription factor activity" (GO: 0003702, P ϭ 0.011, 1.83% of genes concerned).
The Molecular Function GO terms of genes modified in prefrontal cortex after GHB treatment could be classified into two sets: 1) "binding" (GO: 0005488, P ϭ 6.03 ϫ 10 Ϫ5 , 49.70% of genes concerned) and 2) "transcription regulator activity" (GO: 0030528, P ϭ 0.0032, 10.65% of genes concerned).
The "binding" GO term was the most important in number of genes concerned and could be divided into nine significant 1 The online version of this article contains supplemental material. subgroups including "protein binding" (GO: 0005515, P ϭ 0.00231, 29.59% of genes concerned), "nucleic acid binding" (GO: 0003676, P ϭ 0.0168, 15.98% of genes concerned), and "transition metal ion binding" (GO: 0046914, P ϭ 0.0268, 11.83% of genes concerned). The "transcription regulator activity" GO term was only represented by two subgroups.
Biological Process of Genes with Modifications in Their Expression Patterns After Therapeutic Acute Dose of GHB
The probe sets modified by high doses of GHB were in a broad range of Biological Process categories when classified according to GO terms by DAVID. . The GO terms presented are a selected part of the significant GO terms presented in Supplemental Table S1 .
Genes that were significantly altered and could be identified by Biological Process terms were 233 (49.6%) in the hippocampus and 87 (50.6%) in the prefrontal cortex (Supplemental Table S1 ).
A single therapeutic dose of GHB modified several groups of hippocampal genes that could be classified in four general Biological Process GO terms: 1) "metabolic process" (GO: 0008152, P ϭ 1.13 ϫ 10 Ϫ5 , 33.68% of genes concerned), 2) "biological regulation" (GO: 0065007, P ϭ 1.31 ϫ 10 Ϫ4 , 20.71% of genes concerned), 3) "developmental process" (GO: 0032502, P ϭ 0.00403, 14.44% of genes concerned), and 4) "death" (GO: 0016265, P ϭ 5.66 ϫ 10 Ϫ4 , 5.65% of genes concerned). In all these categories, subgroups of GO terms could be identified as significantly modified by GHB treatment (Supplemental Table S1 ). For example, in "metabolic process," we identified 19 subgroups such as "macromolecule metabolic process" (GO: 0043170, P ϭ 1.79 ϫ 10 Ϫ7 , 28.87% of genes concerned), which regroups genes involved in chemical reactions and pathways concerning any molecule of high relative molecular mass (including DNA). "Posttranslational protein modification" (GO: 0043687, P ϭ 5.86 ϫ 10 Ϫ6 , 9.21% of genes concerned) regroups genes involved in the modification of amino acids in a protein after its complete translation and release from the ribosome.
In the "biological regulation" GO term, 16 subgroups could be identified, such as "regulation of signal transduction" (GO: 0009966, P ϭ 7.06 ϫ 10 Ϫ4 , 4.18% of genes concerned), "enzyme-linked receptor protein signaling pathway" (GO: 0007167, P ϭ 0.0087, 2.51% of genes concerned), and "regulation of gene expression" (GO: 0010468, P ϭ 0.0377, 8.58% of genes concerned).
In the "developmental process" GO term, 27 subgroups could be identified, such as "intracellular signaling cascade," the most important population of the group (GO: 0007242, P ϭ 2.36 ϫ 10 Ϫ5 , 9.41% of genes concerned), and "response to stress" (GO: 0006950, P ϭ 0.00205, 6.90% of genes concerned).
In the "death" GO term, three subgroups could be identified, such "programmed cell death," which appears to include the largest part of the general group (GO: 0012501, P ϭ 3.37 ϫ 10 Ϫ4 , 5.65% of genes concerned). In the prefrontal cortex, acute GHB administration altered the expression of several groups of genes that could be classified in four general Biological Process GO terms: 1) "biological regulation" (GO: 0065007, P ϭ 1.46 ϫ 10 Ϫ4 , 26.04% of genes concerned), 2) "developmental process" (GO: 0032502, P ϭ 1.41 ϫ 10 Ϫ4 , 20.71% of genes concerned), 3) "death" (GO: 0016265, P ϭ 2.76 ϫ 10 Ϫ4 , 8.88% of genes concerned), and 4) "immune system process" (GO: 0002376, P ϭ 0.00339, 7.69% of genes concerned). In all these categories, several subgroups of GO terms could be identified as significantly modified by the GHB treatment (Supplemental Table S1 ). For example, in "biological regulation," we identified 29 subgroups including "negative regulation of developmental process" (GO: 0050793, P ϭ 1.21 ϫ 10 Ϫ4 , 5.92% of genes concerned), which is the largest group, or "regulation of cellular metabolic process" (GO: 0031323, P ϭ 0.0012, 14.20% of genes concerned), which regroups genes involved in any processes that modulate chemical reactions and pathways implicated in cellular transformation of chemical substances.
In the "developmental process" GO term, 17 subgroups could be identified, such as "cell development" (GO: 0048468, P ϭ 2.63 ϫ 10 Ϫ5 , 13.02% of genes concerned) and "cell differentiation" (GO: 0030154, P ϭ 8.55 ϫ 10 Ϫ5 , 14.79% of genes concerned).
In the "death" GO term, nine subgroups could be described, such as "apoptosis," which contains the highest number of genes from the general group (GO: 0006915, P ϭ 1.69 ϫ 10 Ϫ4 , 8.88% of genes concerned), and "system development" (GO: 0048731, P ϭ 6.94 ϫ 10 Ϫ4 , 14.20% of genes concerned). In the "immune system process" GO term, 11 subgroups could be identified, such as "myeloid cell differentiation" (GO: 0030099, P ϭ 3.55 ϫ 10 Ϫ4 , 3.5% of genes concerned) and "immune system development" (GO: 0002520, P ϭ 0.0024, 4.14% of genes concerned).
Regarding the statistical treatment of microarray analysis, some conclusions could be established: 1) The majority of genes modified in the hippocampus and/or in the prefrontal cortex were different; only 7.5% were similar.
2) The Biological Process and Molecular Function categories affected by the GHB treatment were globally the same, even if "metabolic processes" were more represented in the hippocampus and "biological regulation" processes were in the majority in the prefrontal cortex.
Regarding details of the genes modified in the two structures by GHB treatment, nine of these were implicated in "cell communication" processes (P ϭ 0.041; 9 genes implicated among the 16 common genes). However, numerous genes modified in the hippocampus or the prefrontal cortex were also implicated in cellular signaling processes.
Considering that probe sets are coding for proteins, we wanted to confirm microarray results by another approach measuring the modification of protein expression after a GHB therapeutic dose, using Western blotting and quantitative immunohistochemistry. The choice of the protein studied was made according to the following criteria: 1) 50% of the tested proteins must be in theory modified in the two brain structures, while the remaining 50% must be modified in only one structure; 2) the proteins tested must have a commercially available antibody that can be used for both Western blot and immunocytochemistry; 3) the proteins must play a role in brain cell signaling; and 4) the proteins must have been implicated in some GHB-related brain mechanism.
On the basis of these criteria eight proteins were selected, and four of these are associated with the pharmacological or physiological role of GHB in brain: dopamine receptor D3 (Drd3), muscarinic 4 receptor (Chrm4), GABA A receptors (Gabrg2), and prolactin receptor (Prlr) (5, 60, 72) . The other four proteins are implicated in cellular signal transduction: dual-specificity phosphatase 1 (Dusp1), serum/glucocorticoid-regulated kinase (Sgk), and brain-specific angiogenesis inhibitor 1-associated protein 2 (Baiap2) exhibit a protein kinase activity, and FBJ murine osteosarcoma viral oncogene homolog (cFos) is considered as a factor of increased transcription in activated neurons.
Western Blot Analysis of Proteins Derived from Selected Modified Genes
The level of each selected protein was explored after immunoprecipitation and Western blotting of total protein from each brain structure (hippocampus and prefrontal cortex) extracted from the brain of treated and control animals. With a specific antibody for each protein, the band that corresponds to the molecular weight of the protein of interest was labeled and quantified with Image J software. For the eight arbitrarily selected proteins, the significant modifications measured by Western blotting were similar compared with the significant modifications measured for corresponding mRNA in microarrays. The amplitude of these modifications induced by the treatment was not exactly the same in both techniques (Fig. 2C) , probably because of regulation cascades between gene transcription and protein synthesis. However, all the genes studied that were up-or downregulated in a given structure also presented the same up or down trend at the protein level in Western blot analysis. More precisely, Chrm4, Baiap2, Dusp1, and Sgk showed an increase in hippocampus and prefrontal cortex, at the level of both gene and protein expression (Fig. 2) . Similarly, the ␥2 chain of GABA A receptors (Gabrg2) and the prolactin receptor (Prlr), which were downregulated only in the prefrontal cortex but not in the hippocampus at the gene level, showed a significant corresponding decrease at the protein level only in the prefrontal cortex. By contrast, Western blot of dopamine receptor D3 and c-Fos demonstrated increased expression only in the hippocampus, where the corresponding genes were upregulated, but no significant change in the prefrontal cortex, where the two genes were not significantly modified.
Immunocytochemical Variations in Expression of Selected Brain Proteins After GHB
To confirm the modifications of the selected proteins shown by Western blot in the hippocampus and prefrontal cortex of GHB-treated animals, we performed an immunohistochemical study of the distribution of these same proteins in hippocampal and prefrontal tissue slices in another group of animals treated identically. Additionally, these studies give some details about the cellular and tissue distribution of the respective proteins. Figure 3 shows the intensity of labeling of prolactin, GABA A (␥2 chain), muscarinic m4, and dopamine D3 receptors and the quantification of this labeling compared with control conditions (arbitrarily set at 100%).
For the cholinergic receptor m4, the increase in labeling in treated rats was obvious in both brain structures at the level of Fig. 2 . Analysis of 8 proteins whose genes were regulated by GHB treatment in the hippocampus and/or in the prefrontal cortex. A: Western blots from proteins extracted from hippocampus or prefrontal cortex, showing GABAA receptor subunit ␥2 (Gabrg2), dopamine receptor D3 (Drd3), prolactin receptor (Prlr), serum/glucocorticoid-regulated kinase 1 (Sgk), dual-specificity phosphatase 1 (Dusp1), brain-specific angiogenesis inhibitor 1-associated protein 2 (Baiap2), FBJ murine osteosarcoma viral oncogene homolog (c-Fos), and muscarinic acetylcholine receptor M4 (Chrm4) immunoreactivity after treatment of rats with vehicle (control) or GHB (1 g/kg) . B: quantification of Western blot results. A significant difference in the level of proteins was observed in rats treated with GHB for all 8 proteins studied. Western blots were analyzed by densitometry, and the values are expressed as % of the control group (injected with saline), which was arbitrarily set at 100%. Student's t-test: *P Ͻ 0.01, **P Ͻ 0.05, ***P Ͻ 0.001. Results represented 3 independent experiments with 3 animals in each group. C: comparison between the amplitude of modifications measured by microarrays and Western blot analysis after GHB treatment. Statistical analysis was performed by Student's t-test on 3 rats in each condition (control and treated rats). FC, fold change. cytoplasm and probably synaptic endings (punctate staining). This increase was greater in the hippocampus (338 Ϯ 24%) than in the prefrontal cortex (264 Ϯ 11%), as previously observed by microarrays and Western blotting.
The dopamine D3 receptor, whose corresponding gene was not significantly altered by the treatment of GHB in the prefrontal cortex, was downregulated in the hippocampus and presented the same profile in immunohistochemistry studies. The images are largely in favor of a reduced staining in hippocampus for treated rats (37 Ϯ 5%), namely at the level of neuronal processes, while for prefrontal cortex no apparent difference (93 Ϯ 4%, P ϭ 0.36) seems to exist between control rats and treated rats. In contrast, we studied two other proteins (GABA A ␥2 receptor and prolactin receptor) whose corresponding genes were not significantly altered in the hippocampus but were downregulated in the prefrontal cortex. Immunochemistry studies carried out with specific antibodies against the corresponding proteins showed no apparent differences Fig. 3 . Immunohistochemical analysis of 4 proteins whose genes were regulated by GHB treatment. Photomicrographs illustrate the difference in the intensity of labeling of Chrm4, Drd3, Gabrg2, and Prlr proteins in the prefrontal cortex and in the hippocampus with or without (control) a single high dose of GHB. Labeling was quantified by densitometry, and values are expressed as % of the control group, which was arbitrarily set at 100%. Chrm4 receptor: control rat structures present light staining compared with those of treated rats, in which staining is strongly increased, particularly at synaptic endings. This is particularly intense in the polymorphic layer of the hippocampus. Drd3 receptor: differences occurred in the hippocampus but not the prefrontal cortex. Controls in the hippocampus presented very high staining, while in tissue slices of treated rats labeling was greatly decreased. This difference did not exist in the prefrontal cortex, where the labeling of Drd3 neurons was identical in control and treated animals. Gabrg2 receptor isoforms: a difference between the intensity of staining was seen only in the prefrontal cortex but not in the hippocampus. Controls in the prefrontal cortex presented very high staining compared with treated rats, which showed a decrease in labeling. In the hippocampus, the labeling of GABAA ␥2 subunit was identical in control and treated rats. Prlr receptor: micrographs demonstrated differences between the 2 groups of rats only in the prefrontal cortex. Controls in the prefrontal cortex exhibited faint labeling surrounding neurons, while in the prefrontal cortex of treated rats there was no labeling. This difference did not exist in the hippocampus: the labeling of Prlr neurons was similar in control and treated rats. Student's t-test: ***P Ͻ 0.001. Results represent 3 independent experiments with 3 animals in each group. Scale bars, 40 m.
(95 Ϯ 6% and 104 Ϯ 4% respectively for the GABA A ␥2 and prolactin receptors) between control rats and treated rats in the hippocampus (Fig. 3) . However, staining of the two proteins was strongly reduced compared with controls under the same conditions in the prefrontal cortex (51 Ϯ 2% and 51 Ϯ 1%, respectively, for GABA A ␥2 and prolactin receptors). Figure 4 shows the intensity of labeling of Baiap2, Dusp1, c-Fos, and Sgk protein in both prefrontal cortex and hippocampus of either GHB-treated or untreated rats. Baiap2 [insulin receptor substrate p53 (IRSp53) or brain angiogenesis inhibitor associated 1 protein 2 (62) ] is an adapter protein, which interacts with the Rho family of GTPases and mediates neurite Fig. 4 . Quantitative immunohistochemical analysis of 4 proteins regulated by GHB treatment. Photomicrographs illustrate the difference in the intensity of labeling of Baiap2, Dusp1, Sgk, and c-Fos proteins in prefrontal cortex and hippocampus of control or treated rats. Labeling was quantified by densitometry, and values are expressed as % of the control group, arbitrarily set at 100%. Baiap2 protein: control rats in the prefrontal cortex presented very slight staining compared with rats treated with GHB, which exhibited an increase in both labeling intensity and number of stained neurons. This phenomenon was also observed in the hippocampus, where the labeling of Baiap2 neurons was very faint in control rats, while after treatment both the number of stained neurons and staining intensity increased considerably. Dusp1 protein: micrographs confirm the difference existing between treated and nontreated rats in both structures. Control prefrontal cortex presented a very slight staining compared with rats treated with GHB, which showed increased labeling intensity and numbers of labeled neurons. This difference existed also in hippocampus, where labeling of Dusp1 neurons was very discrete in control rats. In treated rats, the number of neurons stained increased considerably together with the intensity of labeling. Sgk protein: same comments as for Baiap2 and Dusp1 concerning differences in the intensity of labeling of Sgk neurons in the prefrontal cortex and hippocampus of control and treated rats. Controls presented light staining in prefrontal cortex and hippocampus compared with treated rats. c-Fos protein: controls in prefrontal cortex presented no differences in staining compared with treated rats, but in hippocampus labeling of c-Fos was increased in treated rats compared with control rats. Student's t-test: ***P Ͻ 0.001. Results represent 3 independent experiments with 3 animals in each group. Scale bars, 40 m. outgrowth. Our immunohistochemical study revealed that control rats presented a slight labeling in neurons of the prefrontal cortex, essentially in the cytoplasm and neuronal processes. GHB treatment markedly increased the expression of Baiap2 protein in neuronal cytoplasm and processes, and in addition the number of positive neurons was also higher (223 Ϯ 27%, P Ͻ 0.0001). In the hippocampus, the same phenomenon was observed with a very discrete labeling in control rats compared with a much higher signal in a higher number of neurons in GHB-treated rats (222 Ϯ 30%, P Ͻ 0.0001). This staining was more abundant in polymorphic layers of the dentate gyrus and in the hilar border of the granule cell layer.
For Dusp1 protein, immunohistochemical studies also confirmed the increase of this protein after GHB treatment in hippocampus and prefrontal cortex [242 Ϯ 13% (P Ͻ 0.0001) and 216 Ϯ 11% (P Ͻ 0.0001), respectively]. DUSPs are a group of enzymes that belong to the superfamily of protein tyrosine phosphatases (66) . They are able to recognize phospho-Ser/Thr and phospho-Tyr residues in substrates. Human Dusp1 has been identified as an immediate-early gene whose expression is rapidly induced by oxidative stress, heat shock, and growth factors (14) . The distribution of Dusp1 protein was essentially in the cytoplasm and processes of neurons. In treated rats, the intensity of staining increased considerably but the number of reactive neurons appeared to be the same. The labeling increased more in the cytoplasm than in neuronal processes, but dense punctate structures were frequently seen. In the hippocampus, the staining of Dusp1 was marked within the granule cell layer, particularly in processes and synaptic endings of these neurons, and much more intense in GHBtreated rats.
Serum/glucocorticoid-regulated kinase (Sgk) proteins were strongly increased in both hippocampus and prefrontal cortex after GHB treatment according to immunohistochemical experiments [438 Ϯ 40% (P Ͻ 0.0001) and 327 Ϯ 33% (P Ͻ 0.0001), respectively], in accordance with the increased gene expression in these regions. The Sgk gene was originally identified as a member of the serine/threonine protein kinase gene family that is induced transcriptionally by glucocorticoid and serum (73) . Previous studies revealed that Sgk mRNA was expressed uniformly throughout the rat brain and especially in the CA3 of the hippocampus (68) . Figure 4 shows the increase in Sgk protein in GHB-treated rats, especially in the CA3 region of the hippocampus, where neurons were heavily labeled in both the cytoplasm and processes. Finally, for c-Fos protein, the images suggest heavier staining in hippocampus (189 Ϯ 9%, P Ͻ 0.0001) but not prefrontal cortex (107 Ϯ 6%, P ϭ 0.260). Staining in hippocampus was increased in the cytoplasm and processes and revealed that GHB activated the hippocampal neurons.
DISCUSSION
The present study shows that a single acute therapeutic/ anesthetic dose of GHB administered to rats modifies a whole population of genes during the period of pharmacological effects of the drug in the hippocampus and prefrontal cortex. The GHB dose of 1 g/kg was chosen for two main reasons. First, the GHB-induced concentration in the brain of treated animals must be high enough to provoke deep sleep in all of them, in order to mimic the main effect of GHB used therapeutically (narcoleptic patients or anesthetic purposes). The neuroprotective effects of GHB described in several models also required high GHB concentrations (25) , while by contrast low concentrations seemed to possess neurotoxic properties (55) . Second, we have recently shown (43) that a GHB dose of 1 g/kg in rats induced a concentration of this substance in brain of ϳ1-1.5 mM. This concentration was necessary to significantly modify the degree of histone H3 acetylation and to change gene expression in the rat brain.
The study focused on two important brain regions that are concerned with GHB mechanisms because they express a high density of GHB receptors (32) . Under these conditions, Ͼ200 genes in the hippocampus and/or in the prefrontal cortex significantly change their expression 2 h after an intraperitoneal injection of 1 g/kg GHB compared with controls. These genes code for a large variety of different proteins implicated in various functions such as binding to different kinds of molecules. This seems to indicate that GHB particularly induced proteins implicated in selective, noncovalent interactions with one or more specific sites on another molecule, principally another protein (40% of genes in the hippocampus and 29% in the prefrontal cortex) or a nucleic acid (10% of genes in the hippocampus and 15% in the prefrontal cortex). However, in the hippocampus another molecular function identified as "catalytic activity" is very important (22% of genes) and regroups all the biochemical reactions that occur at physiological temperatures. These enzymes possess specific binding sites for substrates and cofactors. In addition, hippocampus is principally the source of "metabolic processes" (33% of genes concerned) after a single high dose of GHB, compared with prefrontal cortex, where modified genes were mainly implicated in "biological regulation" activities (26% of genes concerned). Both structures exhibited a battery of modified genes that could be implicated in pharmacological mechanisms driven by GHB. For example, GHB is considered a neuromodulator in the central nervous system (12, 49) . The existence of endogenous GHB in brain with high-affinity binding sites and specific enzymatic machinery, together with transport and release mechanisms for this substance, is generally accepted (40, 50) . It is also known that peripheral administration of GHB in animals and humans modifies the turnover of several neurotransmitters, hormones, and cell signals (28, 29, 72) . These properties of GHB could be explained in part by the modification of several genes playing a role in general processes like "regulation of signal transduction," "enzyme-linked receptor protein signaling pathway," "phosphorylation," or "intracellular signaling cascade," especially in the hippocampus. In the prefrontal cortex, modified genes belong more specifically to other groups, referenced as "transmission of nerve impulse," "synaptic transmission," or "response to hormone stimulation." On the other hand, much data supports GHB as involved in cellular protection, particularly in brain (48, 52) , and this property is largely represented by the significant implication of GHB treatment in biological processes like "death" and "programmed cell death" in both structures, but also by "immune system processes" specific to the prefrontal cortex or "responses to stress" within the hippocampus.
However, in all biological processes modified by a single high dose of GHB, no specific item (except "rhythmic processes") implicated GHB for its properties as a sleep inducer, and only one gene (Per1), specifically involved in the sleep process (7, 53) , was modified by GHB treatment.
Nevertheless, the analysis of gene populations whose expression was modified by a single therapeutic dose of GHB gives new insight into brain mechanisms altered by GHB treatment and indicates some new tracks for future studies. For example, the gene cluster implicated in the general category of "developmental process" with specific items concerning "nervous system development" and "cell differentiation," modified by GHB treatment in both structures, are biological processes that have never been associated with GHB, at the pharmacological or physiological level. In addition, the present results argue for GHB playing a role in neuronal and synaptic plasticity because of at least three genes whose expression was regulated by GHB in the prefrontal cortex and implicated in "regulation of neuronal synaptic plasticity" or "neurogenesis."
We also identified in both brain regions a few sets of genes whose expression was the most modified by the treatment and 16 genes simultaneously regulated in these two brain regions. In regard to all the genes modified, it was not possible to identify specific functions or pathways under control. However, some of these genes are at the basis of important cell or neuronal functions.
In hippocampus, 11 genes were upregulated and 10 genes downregulated more than threefold. Among them, transportin 1 (Tnpo1, 12-fold increase) is a transporter/receptor protein that translocates substrates from the cytoplasm to the nucleus through nuclear pore complexes by recognizing nuclear localization signals (NLSs) (38) . Heat shock 70-kDa protein 1a (Hspa1a, 7-fold increase) which is highly inducible, exhibits the major chaperoning activities within the cytoplasm and participates in de novo protein folding and refolding of damaged or misfolded proteins. Several genes are involved in transcription processes, such as Jun b, c-Fos, transcription elongation factor B (Tceb3), and bromodomain containing 4 (Brd4), which is a double bromodomain-containing protein that binds preferentially to acetylated chromatin (H3 and H4) (20) . These genes are induced by 3-to 5.5-fold after GHB treatment. The 10 downregulated genes are mainly implicated in cell signaling. Among them, rabphilin 3A-like (without C2 domains) (4-fold) is a neural/neuroendocrine-specific member of the Rab family involved in Ca 2ϩ -regulated exocytosis, where it functions in an inhibitory capacity controlling recruitment of secretory vesicles into a releasable pool at the plasma membrane (30) . Transmembrane channel-like gene family 4 (3.8-fold) may function as a ion channel or transporter, or as a modulator of these proteins (45) . Mitogen-activated protein kinase 4 (3.7-fold) is a member of the mitogen-activated protein kinases (MAPKs) that represent a family of evolutionarily conserved enzymes with a central role in the wellcharacterized MAPK signaling cascades. A wide variety of extracellular stimuli (including GHB) (57) serve as activators of MAPK pathways leading to appropriate cellular responses, such as proliferation, differentiation, growth, and migration (64) .
In the prefrontal cortex, 21 genes were up-or downregulated by a factor of around two-to threefold. These genes were principally involved in stress responses and neuronal plasticity. Interestingly, period homolog 1 (Per1; 2.8-fold), encodes one of the essential elements involved in the transcription/translation-based autoregular loop of the endogenous master clock (58) . Nuclear factor of light chain gene enhancer in B cells inhibitor ␣ (2.6-fold) inhibits the activity of dimeric NF-B/ REL complexes by trapping REL dimers in the cytoplasm through masking their nuclear localization signals (67) . Early growth response 2 (2.42-fold) has a sequence-specific DNAbinding transcription factor and binds to two specific DNA sites located in the promoter region of HOXA4. This factor may activate the transcription of common target genes that are required for persistent neural activity including the maintenance of certain forms of activity-dependent neural plasticity (19) . Hairy and enhancer of split 1 (2.4-fold) is a transcription factor. This rat gene is rapidly induced by growth factors known to influence neuronal differentiation (4, 37) . Growth arrest and DNA damage-inducible 45␤ (2.3-fold) is implicated in neuroprotection (34, 44) , and serine/threonine kinase 4 (Stk4; 2.2-fold) is a stress-activated, proapoptotic kinase that, after caspase cleavage, enters the nucleus and induces chromatin condensation followed by internucleosomal DNA fragmentation. Stk4 phosphorylates "Ser-14" of histone H2B during apoptosis and phosphorylates FOXO3 upon oxidative stress, resulting in its nuclear translocation and cell death initiation (15) . CCAAT/enhancer binding protein delta (C/EBP␦; 2.2-fold) plays a role in cell differentiation and inflammatory reactions (17) .
If we consider the gene pattern modified similarly in both brain structures, 16 genes were found, 15 upregulated and only 1 downregulated. These genes are implicated in cell communication (neuronal signaling, stress response, etc.), metabolic processing, or regulation of transcription. Only one gene showed an increased expression of greater than fourfold, and moreover it was represented by two different probe sets. The associated gene or protein was the soluble glycerol-3-phosphate dehydrogenase 1 (Gdp1). This enzyme is involved in mitochondrial hydrogen shuttles necessary for the reoxidation of glycolysis-derived NADH. Activated Gdp1 increases intracellular levels of NADH and increases cellular resistance against H 2 O 2 injury (35) .
The existence of numerous targets and functions for endogenous GHB supports its role as a neurotransmitter in brain and could explain its role as a modulator of other neurotransmitter systems both at physiological doses and at higher concentrations. GABAergic and dopaminergic systems are mainly implicated in mechanistic models to explain the effects of GHB at various doses (21, 24, 28, 71) . These reasons led us to focus on neuronal receptors and ions channels that adapt their expression when being directly or indirectly stimulated by GHB. In hippocampus, neuropeptide Y2, muscarinic 4, opioid 1, ␤3 adrenergic, and dopamine D3 were among the neurotransmitter receptors up-or downregulated by GHB. It could be speculated that the corresponding neurotransmitters might be involved in the mechanism of action of GHB, and some results support the implication of acetylcholine, opiates, and dopamine (29, 36, 60, 61) . In prefrontal cortex, muscarinic 4 receptor was also upregulated, and this phenomenon could be the result of reduced stimulation of this cholinergic receptor, which functions mainly as an autoreceptor. Interestingly, the ␥2 chain of GABA A receptor was downregulated by the drug. This could be due to a sustained hyperstimulation because GABA A receptors seem to play a pivotal role in the functional and pharmacological effects of GHB (1, 5, 10, 16, 23, 63) . The majority of GABA A receptors contain a ␥2 subunit, expressed throughout the brain except in the thalamus. It is well known that GHB administration in rats modifies GABA release in brain (9, 10, 28) , leading to a pharmacological profile (sleep, anesthesia, anxiolysis) similar to those described for other GABA A agonists.
To confirm array data, we arbitrarily selected eight genes whose products appeared to be of fundamental interest and quantitatively assessed their differential expression, using Western blotting of corresponding proteins. In a second step, immunohistochemical studies were carried out with the same antibodies as for Western blots, to obtain a measurement of tissue levels and distribution of the various modified proteins. However, among the selected gene products, at least four (muscarinic receptor type 4, dopamine receptor type 3, ␥2 subunit of GABA A receptors, prolactin receptor) could be considered as implicated directly or indirectly in the mechanism of GHB action in brain (18, 27, 60, 65) . Chrm4, Baiap2, Dusp1, and Sgk proteins were elevated significantly in both brain regions, corresponding to what was observed for their corresponding genes. These results were confirmed by the corresponding immunohistochemical images of hippocampal and prefrontal cortex tissue obtained from rats treated with GHB in a manner identical to microarray experiments. Gabgr2 and prolactin receptor proteins (65) were both downregulated in prefrontal cortex but not significantly altered in hippocampus, consistent with the microarray data. For Drd3, Western blot, immunocytochemical images, and gene studies were also in accordance since this dopamine receptor was downregulated in hippocampus but not significantly in prefrontal cortex. Alternatively, c-Fos gene showed a trend to increase its expression in the prefrontal cortex of treated rats, but the result was not significant. In Western blot analysis no modification of c-Fos protein was observed. However, immunohistochemical results for this protein in prefrontal cortex demonstrated the presence of clusters of activated neurons, whereas the majority of neurons presented no modifications in c-Fos expression in the prefrontal cortex. In the hippocampus, all results were in favor of an increase in c-Fos expression in microarray, Western blot, or immunohistochemical studies.
The induction of c-Fos protein in various regions of rat brain has been studied by several authors after administration of GHB (69) . Our study confirms and extends this result to the hippocampus, a region that expresses a dense population of GHB receptor(s) and binding sites and demonstrates an upregulation of the corresponding gene. A recent publication pointed to the fact that the GHB-induced accumulation of c-Fos is somewhat different from that induced by baclofen administration (70) . In addition to this study, genomic experiments have shown that cultured hippocampal neurons stimulated by baclofen exhibit a profile of changes in gene expression containing several genes that are almost entirely absent from the present sets of gene modified by GHB (26) . For example, ␤-adrenergic receptor, which was upregulated by baclofen in primary cultures of hippocampal neurons, was downregulated in hippocampus in our present study carried out after GHB administered in vivo. These results represent additional evidence suggesting that the mechanisms of action of GHB and of the GABA B reference agonist (baclofen) are different in many aspects, including acute changes in brain gene expression.
